Does Blue Cross Blue Shield of Massachusetts Cover Farxiga?

How BCBSMA Formulary Placement Works for Farxiga

Blue Cross Blue Shield of Massachusetts maintains a multi-tier formulary that determines patient cost-sharing for covered medications. Farxiga sits on Tier 3 (preferred brand) for most commercial HMO and PPO plans, though certain Medicare Advantage products may classify it differently. The specific tier affects whether you pay a flat copay or percentage-based coinsurance [1].

Understanding Tier Structure

BCBSMA commercial plans typically use a four- or five-tier structure. Tier 1 covers generics at the lowest cost. Tier 2 includes preferred brands. Tier 3 holds non-preferred brands or specialty medications. For Farxiga specifically, placement depends on which plan year and product line you purchased. The formulary updates at least annually, with mid-year changes possible after FDA label expansions [2].

Why SGLT2 Inhibitors Earned Formulary Preference

The FDA approved dapagliflozin for type 2 diabetes in 2014, then expanded the label to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 [3]. These expanded indications, supported by landmark trials, pushed most large insurers including BCBSMA to maintain coverage rather than exclude the drug class entirely. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin versus placebo [4]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite renal endpoint regardless of diabetes status [5].

Checking Your Specific Plan

Members can verify coverage by logging into the BCBSMA member portal, calling the number on their insurance card, or asking their pharmacist to run a test claim. Formulary documents are also available on the BCBSMA website by plan type and year.

Prior Authorization Requirements

Most BCBSMA plans require prior authorization (PA) before filling a Farxiga prescription. This means your prescriber must submit clinical documentation proving medical necessity. The insurer reviews the request against established criteria before approving or denying coverage [6].

Common PA Criteria for Farxiga

For a type 2 diabetes indication, BCBSMA typically requires documentation that the patient has tried and failed (or has a contraindication to) metformin. Some plans also require an HbA1c value above a specific threshold, often 7.0% or higher, with lab results dated within the prior 90 days [7]. The American Diabetes Association (ADA) 2024 Standards of Care recommend SGLT2 inhibitors as second-line therapy after metformin, or as first-line in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [8].

PA for Cardio-Renal Indications

When prescribed for heart failure or CKD, the PA criteria differ. Prescribers generally need to document a left ventricular ejection fraction measurement (for HFrEF/HFpEF) or an eGFR between 25 and 75 mL/min/1.73 m² (for CKD). The DELIVER trial (N=6,263) demonstrated that dapagliflozin reduced the composite of cardiovascular death or worsening heart failure by 18% in patients with heart failure and preserved ejection fraction [9].

Turnaround Time and Appeals

Standard PA decisions from BCBSMA arrive within 72 hours for non-urgent requests. Urgent requests receive a 24-hour turnaround. If denied, patients and prescribers can file an appeal within 60 days. Internal data from AstraZeneca's patient support program suggest that approximately 75-80% of PA requests for Farxiga are approved on first submission when documentation is complete [10].

What You Will Pay Out of Pocket

Your actual cost depends on your plan's benefit design, whether you have met your deductible, and whether a copay assistance program applies. Commercial plan members with Tier 3 placement typically see copays between $35 and $75 per month after meeting any applicable deductible [11].

Deductible Phase Costs

High-deductible health plans (HDHPs) offered through BCBSMA may require you to pay full retail price until your deductible is satisfied. The average wholesale acquisition cost for Farxiga 10 mg is approximately $17.94 per tablet, translating to roughly $538 for a 30-day supply at retail [12]. Once the deductible is met, cost-sharing shifts to the plan's coinsurance rate, often 20-30% for brand-name medications.

Medicare Advantage Considerations

BCBSMA Medicare Advantage members may encounter different formulary tiers and cost-sharing structures. Under Medicare Part D, Farxiga falls into the brand-name drug category. The Inflation Reduction Act caps annual out-of-pocket Part D spending at $2,000 starting in 2025, which benefits patients taking expensive brand medications long-term [13].

Copay Assistance Programs

AstraZeneca offers the Farxiga Savings Card for commercially insured patients. Eligible individuals can pay as little as $0 per fill, with a maximum annual benefit that varies by program year. This card cannot be used with Medicare, Medicaid, or other federal healthcare programs [14]. Patients who lack commercial insurance or earn below 400% of the federal poverty level may qualify for AstraZeneca's patient assistance program (AZ&Me), which provides free medication.

Step Therapy and Formulary Alternatives

BCBSMA may impose step therapy, requiring patients to try one or more lower-cost medications before approving Farxiga. The most common required step is metformin, the first-line agent for type 2 diabetes recommended by virtually all major guidelines [15].

SGLT2 Inhibitor Alternatives on Formulary

If Farxiga is non-preferred on your specific plan, empagliflozin (Jardiance) may sit at a lower tier. Both medications belong to the same drug class and share similar cardiovascular and renal benefits. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 14% reduction in the primary composite cardiovascular endpoint with empagliflozin [16]. Canagliflozin (Invokane) is another SGLT2 option, though its formulary position varies more widely across BCBSMA plans due to the amputation signal identified in the CANVAS program [17].

Non-SGLT2 Alternatives

For patients who cannot tolerate SGLT2 inhibitors or who fail step therapy requirements, GLP-1 receptor agonists represent the next preferred class. The ADA Standards of Care position both SGLT2 inhibitors and GLP-1 RAs as preferred add-on therapies for patients with cardiorenal comorbidities [8]. Semaglutide (Ozempic) and dulaglutide (Trulicity) are commonly covered GLP-1 options on BCBSMA formularies, each with their own PA criteria.

Clinical Evidence Supporting Coverage

Insurance coverage decisions rely on clinical trial data demonstrating efficacy and safety. Farxiga's evidence base spans multiple large randomized controlled trials across three distinct patient populations.

Type 2 Diabetes Efficacy

In key trials submitted for FDA approval, dapagliflozin 10 mg reduced HbA1c by 0.5-0.8% versus placebo as monotherapy and as add-on to other glucose-lowering agents [18]. Beyond glycemic control, SGLT2 inhibitors produce modest weight reduction (typically 2-3 kg) and systolic blood pressure lowering (3-5 mmHg) through osmotic diuresis and caloric loss via glycosuria [19].

Heart Failure Outcomes

The combined analysis of DAPA-HF and DELIVER demonstrated consistent benefit across the full spectrum of ejection fraction. A meta-analysis published in The Lancet showed that SGLT2 inhibitors reduced heart failure hospitalizations by 28% and cardiovascular death by 14% across both HFrEF and HFpEF populations [20].

Chronic Kidney Disease Protection

DAPA-CKD enrolled patients with CKD stages 2-4 and elevated albuminuria. Dapagliflozin reduced the primary composite endpoint (sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death) by 39% (HR 0.61, 95% CI 0.51-0.72, P<0.001) [5]. The trial was stopped early for efficacy at a median follow-up of 2.4 years. KDIGO 2024 guidelines now recommend SGLT2 inhibitors for all patients with CKD and albuminuria regardless of diabetes status [21].

How to Get Farxiga Approved by BCBSMA

A systematic approach increases the likelihood of first-pass approval and reduces delays in treatment initiation.

Step 1: Confirm Formulary Status

Contact BCBSMA member services or use the online formulary lookup tool. Confirm the specific tier, any quantity limits, and whether PA or step therapy applies to your plan [22].

Step 2: Gather Clinical Documentation

Your prescriber should document the clinical rationale, including diagnosis codes, relevant lab values (HbA1c, eGFR, UACR, echocardiogram results), and prior medication history. For diabetes indications, document metformin trial duration and outcome. For HF or CKD, document the specific diagnosis and functional class.

Step 3: Submit Prior Authorization

Most BCBSMA PA submissions occur electronically through CoverMyMeds or the BCBSMA provider portal. Include all supporting documentation with the initial submission. Incomplete requests are the most common reason for delays or denials [23].

Step 4: Appeal if Necessary

If denied, request the specific denial reason in writing. Common denial reasons include missing documentation, failure to complete step therapy, or use for an off-label indication. Peer-to-peer reviews between your prescriber and the insurer's medical director can resolve clinical disagreements quickly.

Massachusetts State Coverage Mandates

Massachusetts has among the most comprehensive insurance regulations in the United States. The state's Division of Insurance oversees coverage standards that may affect Farxiga access.

State Parity Requirements

Massachusetts mandates that insurers cannot impose more restrictive utilization management on chronic disease medications than on other covered drugs without clinical justification [24]. This means that if BCBSMA covers other brand-name medications for diabetes management without PA, it faces regulatory pressure to apply similar standards to SGLT2 inhibitors.

MassHealth (Medicaid) Considerations

Patients with MassHealth coverage follow a separate formulary from commercial BCBSMA plans. MassHealth maintains its own preferred drug list, and Farxiga coverage through Medicaid requires a different PA process with criteria aligned to CMS regulations [25].

Safety Monitoring While on Farxiga

Insurance coverage typically assumes appropriate safety monitoring. BCBSMA may require documentation of baseline labs and ongoing monitoring as part of coverage renewal.

Required Baseline Labs

Before initiating dapagliflozin, prescribers should obtain a comprehensive metabolic panel including serum creatinine, eGFR, and potassium. A urinalysis to rule out active urinary tract infection is also recommended [26]. For patients with diabetes, a baseline HbA1c helps establish treatment targets.

Ongoing Monitoring Schedule

The FDA label recommends monitoring renal function periodically. In clinical practice, most providers check eGFR at 1-3 months after initiation and at least annually thereafter. An initial eGFR dip of 10-15% is expected and not a reason to discontinue therapy, as this reflects hemodynamic changes in glomerular filtration rather than structural kidney damage [27].

Key Safety Signals

The FDA prescribing information includes warnings for diabetic ketoacidosis (rare, approximately 0.1-0.2% incidence in trials), genital mycotic infections (occurring in 5-8% of women and 2-4% of men), and volume depletion in elderly patients or those on loop diuretics [28]. Fournier's gangrene is an extremely rare but serious adverse event reported in post-marketing surveillance [29].

Comparing BCBSMA Farxiga Coverage to Other Massachusetts Insurers

BCBSMA is the largest insurer in Massachusetts, but coverage varies across carriers. Harvard Pilgrim Health Care (now part of Point32Health) and Tufts Health Plan also cover Farxiga with similar PA requirements. The key differentiator is tier placement and copay level rather than outright coverage denial.

Employer-Sponsored vs. Individual Plans

Large employer groups often negotiate custom formularies with BCBSMA. A Fortune 500 employer's plan may place Farxiga at a lower tier than an individual marketplace plan purchased through the Massachusetts Health Connector. Patients who switch from employer coverage to an individual plan should verify that their medications remain covered at a similar cost [30].

Dapagliflozin 10 mg taken once daily before the morning meal remains the standard dose for all three FDA-approved indications, with no renal dose adjustment needed until eGFR falls below 25 mL/min/1.73 m² [3].